{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:39:27Z","timestamp":1787812767116,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd011395","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000}}],"reference-count":80,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011395.pub2","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T21:43:45Z","timestamp":1619127825000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer"],"prefix":"10.1002","volume":"2021","author":[{"given":"Amelia M","family":"Taylor","sequence":"additional","affiliation":[{"name":"Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Lok Hang","family":"Chan","sequence":"additional","affiliation":[{"name":"Medical Oncology; Royal North Shore Hospital; Sydney Australia"},{"name":"Faculty of Medicine and Health, Northern Clinical School; University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tio","sequence":"additional","affiliation":[{"name":"Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata M","family":"Patil","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A","family":"Traina","sequence":"additional","affiliation":[{"name":"Department of Medicine; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College; New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Robson","sequence":"additional","affiliation":[{"name":"Department of Medicine; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College; New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney; Camperdown Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0001|cit1","first-page":"Abstract nr OT1","article-title":"A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study)","volume":"76","author":"Balmana","year":"2016","journal-title":"Cancer Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0002|cit2","first-page":"Abstract nr SAB","article-title":"Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C\/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer","volume":"77","author":"Di\u00e9ras","year":"2017","journal-title":"Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD011395.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0004|cit4","first-page":"Abstract nr SAB","article-title":"Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C\/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study","volume":"77","author":"Han","year":"2017","journal-title":"Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD011395.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/fon-2016-0412","article-title":"A randomized Phase II study of veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in BRCA1\/2 metastatic breast cancer: design and rationale","volume":"13","author":"Isakoff","year":"2017","journal-title":"Future Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0006|cit6","first-page":"Abstract nr PD4","article-title":"First-line veliparib plus carboplatin\/paclitaxel in patients with HER2-negative advanced\/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial","volume":"80","author":"Arun","year":"2020","journal-title":"Cancer Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011395.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.annonc.2020.03.241","article-title":"Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced\/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial","volume":"31","author":"Ayoub","year":"2020","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011395.pub2-BIB0008|cit8","first-page":"v851","article-title":"A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer","volume":"30","author":"Dieras","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2019.37.15_suppl.1044","article-title":"Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1\/2-mutated (gBRCAm) locally advanced\/metastatic breast cancer (LA\/MBC) in the EMBRACA study","volume":"37","author":"Diab","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2018.36.15_suppl.1070","article-title":"Analysis of germline BRCA1\/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA)","volume":"36","author":"Eiermann","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.2019.37.15_suppl.1071","article-title":"Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial","volume":"37","author":"Ettl","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011395.pub2-BIB0012|cit12","first-page":"v129-30","article-title":"Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1\/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician\u2019s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with\/without visceral disease","volume":"30","author":"Ettl","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011395.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"iii52","DOI":"10.1093\/annonc\/mdz100.013","article-title":"Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1\/2 mutation (gBRCAm) in EMBRACA","volume":"30","author":"Ettl","year":"2019","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011395.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","article-title":"Quality of life with talazoparib versus physician\u2019s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial","volume":"29","author":"Ettl","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011395.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/annonc\/mdz100.005","article-title":"Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1\/2 (gBRCA) mutation in the phase III EMBRACA trial","volume":"30","author":"Fasching","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011395.pub2-BIB0016|cit16","first-page":"viii96-7","article-title":"EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1\/BRCA2 subgroup analysis","volume":"29","author":"Gon\u00e7alves","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011395.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0960-9776(19)30743-X","article-title":"Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1\/2m) subgroups","volume":"48","author":"Goncalves","year":"2019","journal-title":"Breast"},{"issue":"3","key":"10.1002\/14651858.CD011395.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","article-title":"Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial","volume":"25","author":"Hurvitz","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"10.1002\/14651858.CD011395.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"ix14","DOI":"10.1093\/annonc\/mdz418.001","article-title":"Talazoparib (TALA) vs physician\u2019s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1\/2 mutation (gBRCA1\/2mut): data from phase III EMBRACA","volume":"30","author":"Lee","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0020|cit20","first-page":"Abstract nr OT2","article-title":"A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and\/or metastatic breast cancer (EMBRACA)","volume":"77","author":"Litton","year":"2017","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0021|cit21","unstructured":"Litton J Rugo HS Ettl J Hurvitz S Goncalves A Lee KH EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician\u02bcs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract] San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX) San Antonio (TX) 2017"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD011395.pub2-BIB0022|cit22","first-page":"Abstract no. CT","article-title":"Talazoparib (TALA) in germline BRCA1\/2 (gBRCA1\/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial","volume":"80","author":"Litton","year":"2020","journal-title":"Cancer Research"},{"issue":"8","key":"10.1002\/14651858.CD011395.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011395.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"viii96","DOI":"10.1093\/annonc\/mdy272.293","article-title":"EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1\/2 mutation (gBRCAm), and prior platinum treatment","volume":"29","author":"Mart\u00edn","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0025|cit25","first-page":"Abstract nr P6","article-title":"EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1\/2 mutation: a regional analysis","volume":"79","author":"Mina","year":"2019","journal-title":"Cancer Research"},{"issue":"Suppl 10A","key":"10.1002\/14651858.CD011395.pub2-BIB0026|cit26","first-page":"S37","article-title":"Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1\/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups","volume":"25","author":"Quek","year":"2019","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011395.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S532","DOI":"10.1016\/j.jval.2019.09.683","article-title":"Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with\/without prior chemotherapy (CT) subgroups","volume":"22","author":"Quek","year":"2019","journal-title":"Value in Health"},{"issue":"1","key":"10.1002\/14651858.CD011395.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"pkz085","DOI":"10.1093\/jncics\/pkz085","article-title":"Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy","volume":"4","author":"Rugo","year":"2020","journal-title":"Journal of the National Cancer Institute Cancer Spectrum"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2018.36.15_suppl.1069","article-title":"EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation","volume":"36","author":"Rugo","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011395.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"viii91","DOI":"10.1093\/annonc\/mdy272.284","article-title":"Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1\/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician\u2019s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation","volume":"29","author":"Rugo","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011395.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"viii97","DOI":"10.1093\/annonc\/mdy272.295","article-title":"Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1\/2 mutations receiving talazoparib in the phase III EMBRACA trial","volume":"29","author":"Yu","year":"2018","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011395.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/jcph.1623","article-title":"Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA trial","volume":"60","author":"Yu","year":"2020","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011395.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"355-63","DOI":"10.1007\/s10637-016-0335-x","article-title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","volume":"34","author":"Kummar","year":"2016","journal-title":"Investigational New Drugs"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011395.pub2-BIB0034|cit34","first-page":"v74","article-title":"OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician\u2019s choice","volume":"28","author":"Delaloge","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0035|cit35","first-page":"Abstract nr P5","article-title":"Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD","volume":"78","author":"Domchek","year":"2018","journal-title":"Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD011395.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"8753","DOI":"10.1038\/s41598-020-63033-4","article-title":"Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis","volume":"10","author":"Im","year":"2020","journal-title":"Scientific Reports"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0037|cit37","first-page":"Abstract nr P5","article-title":"Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial","volume":"78","author":"Im","year":"2018","journal-title":"Cancer Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0038|cit38","first-page":"Abstract nr P6","article-title":"Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes","volume":"80","author":"Merens","year":"2020","journal-title":"Cancer Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011395.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jval.2018.04.058","article-title":"Estimating the health state utility of patients with HER2-gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial","volume":"21","author":"Robson","year":"2018","journal-title":"Value in Health"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011395.pub2-BIB0040|cit40","first-page":"Abstract nr PD4","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"80","author":"Robson","year":"2020","journal-title":"Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD011395.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2019.06.023","article-title":"Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial","volume":"120","author":"Robson","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011395.pub2-BIB0043|cit43","first-page":"v74","article-title":"OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician\u2019s choice (TPC)","volume":"28","author":"Robson","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD011395.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"CT038","DOI":"10.1158\/1538-7445.AM2018-CT038","article-title":"Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)","volume":"78","author":"Robson","year":"2018","journal-title":"American Association for Cancer Research"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD011395.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA4","article-title":"OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)","volume":"35","author":"Robson","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2018.36.15_suppl.1045","article-title":"EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician\u2019s choice (TPC) in OlympiAD","volume":"36","author":"Robson","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011395.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(18)30285-5","article-title":"Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD","volume":"92","author":"Senkus-Konefka","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0049|cit49","first-page":"1053","article-title":"Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases","volume":"36","author":"Tung","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/jco.2014.32.15_suppl.1019","article-title":"Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146","volume":"32","author":"Dwadasi","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011395.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011395.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"205-14","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O'Shaughnessy","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"34","key":"10.1002\/14651858.CD011395.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O'Shaughnessy","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD011395.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.2019.37.15_suppl.1092","article-title":"RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD)","volume":"37","author":"Patsouris","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011395.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011395.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO)","volume":"25","author":"Turner","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011395.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"v67","DOI":"10.1093\/annonc\/mdx362.065","article-title":"OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1\/2 mutation (gBRCAm)","volume":"28","author":"Tutt","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011395.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"TPS596","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS596","article-title":"KEYLYNK-009: a phase II\/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","volume":"38","author":"Rugo","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"7306","key":"10.1002\/14651858.CD011395.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/bmj.323.7306.224","article-title":"Systematic reviews of evaluations of prognostic variables","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD011395.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.18632\/oncotarget.5367","article-title":"Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Bao","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1002\/14651858.CD011395.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","article-title":"A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG oncology\/gynecologic oncology group study","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011395.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society"},{"issue":"23","key":"10.1002\/14651858.CD011395.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.2174\/092986712802002464","article-title":"Role of PARP inhibitors in cancer biology and therapy","volume":"19","author":"Davar","year":"2012","journal-title":"Current Medicinal Chemistry"},{"issue":"20","key":"10.1002\/14651858.CD011395.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0065|cit65","unstructured":"McMaster University GRADEprofiler (GRADEpro) 2014"},{"issue":"7650","key":"10.1002\/14651858.CD011395.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0067|cit67","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"issue":"3-5","key":"10.1002\/14651858.CD011395.pub2-BIB0068|cit68","first-page":"Abstract HSR19","article-title":"Incidence of adverse events following use of different PARP inhibitors: systematic review and meta-analysis","volume":"17","author":"Ho","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network: National Compehensive Cancer Network Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, NCCN"},{"issue":"11","key":"10.1002\/14651858.CD011395.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.4155\/cli.11.132","article-title":"Poly (ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges","volume":"1","author":"Khasraw","year":"2011","journal-title":"Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD011395.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1078-0432.CCR-11-1973","article-title":"Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor","volume":"18","author":"Liu","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0936-6555(05)80448-0","article-title":"Thirty years of Medical Research Council randomized trials in solid tumors","volume":"9","author":"Machin","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0072|cit72","first-page":"665","article-title":"PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues","volume":"2","author":"Murthy","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0073|cit73","unstructured":"Breast Cancer oncologypro.esmo.org\/Oncology-in-Practice\/Anti-Cancer-Agents-and-Biological-Therapy\/PARP-inhibition-and-DNA-Damage-Response-DDR\/PARP-inhibitors\/Clinical-Activity\/Breast-Cancer\/Ongoing-Developments"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"6797","key":"10.1002\/14651858.CD011395.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1002\/14651858.CD011395.pub2-BIB0076|cit76","first-page":"e000361","article-title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"3","author":"Poggio","year":"2018","journal-title":"European Society for Medical Oncology Open"},{"key":"10.1002\/14651858.CD011395.pub2-BIB0077|cit77","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"22","key":"10.1002\/14651858.CD011395.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011395.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1002\/14651858.CD011395.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"A randomised phase III trial of carboplatin compared with docetaxel in BRCA1\/2 mutated and pre-specified triple negative breast cancer \u201cBRCAness\u201d subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nature Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:19:39Z","timestamp":1724905179000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011395.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Breast Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011395.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]}}}